TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23679147

Group type: EXPERIMENTAL
Intervention: Supramaximal interval training (SMIT), n=20, 30 s at 130% AV, 150 s passive recovery, 7-12 bouts per session
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group, n=16, 30 min continuous running at 75% AV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT), n=19, 4 min at 100% AV, 4 min passive recovery, 4-6 bouts per session
Number of subjects: 75
Study: 21371242

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin once daily for 6 months
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 19645619

Group type: EXPERIMENTAL
Intervention: Strengths-based linkage intervention
Number of subjects: 316

Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 316
Study: 16882804

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 without electrolytes
Number of subjects: 79

Group type: COMPARATOR
Intervention: Milk of magnesia
Number of subjects: 79
Study: 15542191

Group type: EXPERIMENTAL
Intervention: Recombinant CMV gB vaccine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: gB canarypox vectored vaccine (ALVAC‐CMVgB)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Purified protein subunit with adjuvant
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Recombinant canarypox
Number of subjects: 76
Study: 11715153

Group type: EXPERIMENTAL
Intervention: Polysaccharide pneumococcal vaccine
Number of subjects: 0
Study: 9287241

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-beta 1a (IFN-beta 1a)
Number of subjects: 793

Group type: COMPARATOR
Intervention: CHO-derived IFN-beta 1a
Number of subjects: 793
Study: 7902905

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Risk factors (age > 65 years, body weight < 70 kg, hypertension on admission)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 444
Study: 3012807

Group type: EXPERIMENTAL
Intervention: Restriction endonuclease digestion of DNA from herpes simplex virus isolates
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (5 of the 40 isolates)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sequential isolates from a patient cleaved with Eco R1 and Hind III
Number of subjects: 40
Study: 29694465

Group type: EXPERIMENTAL
Intervention: Melatonin (12 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26681487

Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 85

Group type: COMPARATOR
Intervention: No booklet (control)
Number of subjects: 85
Study: 25516139

Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin D3 monthly for two months then 100,000 IU monthly for a total of 18 months
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 22800449

Group type: EXPERIMENTAL
Intervention: +3.00 D aspheric AcrySof ReSTOR IOL
Number of subjects: 60

Group type: COMPARATOR
Intervention: +4.00 D aspheric AcrySof ReSTOR IOL
Number of subjects: 60
Study: 21092604

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 271
Study: 18728266

Group type: EXPERIMENTAL
Intervention: Allopurinol, 200 mg twice daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15749447

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO), n=18
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unicompartmental knee arthroplasty (UKA), n=22
Number of subjects: 40
Study: 14651755

Group type: EXPERIMENTAL
Intervention: Evidence Based Medicine (EBM) Knowledge Score; average score on the 12-point scale was 6.4; over 50% of respondents answered questions satisfactorily regarding critical appraisal methods and interpretation of results.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Importance of EBM principles to practice; 95% of respondents felt EBM principles were important.
Number of subjects: 1000
Study: 10394342

Group type: EXPERIMENTAL
Intervention: Philips SL‐25 linear accelerator (SL‐25‐MLC) with 6 MV photons and MLC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Philips SL‐75 linear accelerator (SL‐75) with 5 MV photons and tray‐mounted cerrobend blocks
Number of subjects: 20
Study: 8961779

Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative treatment or placebo
Number of subjects: 0
Study: 1996745

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% at 37 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% at room temperature
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% at 4 degrees C
Number of subjects: 30
Study: 6435703

Group type: EXPERIMENTAL
Intervention: Buserelin alone (group A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Buserelin with tamoxifen (group B)
Number of subjects: 17
Study: 31761834

Group type: EXPERIMENTAL
Intervention: BYM338 (bimagrumab) at doses of 10 mg/kg, 3 mg/kg, and 1 mg/kg administered intravenously every 4 weeks for 52 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BYM338 (bimagrumab)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28386694

Group type: EXPERIMENTAL
Intervention: Alcohol (1.09 g ethanol kg-1 fat-free body mass)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Alcohol and Placebo (combined results)
Number of subjects: 13
Study: 26773752

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 148
Study: 24373114

Group type: EXPERIMENTAL
Intervention: Teaching group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 22455402

Group type: EXPERIMENTAL
Intervention: SB-PACT web-based system
Number of subjects: 100
Study: 18547778

Group type: EXPERIMENTAL
Intervention: Social Behavior and Network Therapy
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: General factors (not specific to treatment)
Number of subjects: 397
Study: 17478412

Group type: EXPERIMENTAL
Intervention: Interactive patient website
Number of subjects: 37
Study: 15023830

Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 12 treatments over three months)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 401
Study: 11779264

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d or 120 mg/d)
Number of subjects: 7290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7290
Study: 9555668

Group type: EXPERIMENTAL
Intervention: Intravenous iron-saccharate and rhEPO treatment in group II patients
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous iron-saccharate and rhEPO treatment in group IV patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy subjects (group I)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Absolute iron deficiency in group III patients
Number of subjects: 6
Study: 8288664

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 grams followed by 750 mg at 8 and 16 hours later for a total of one day)
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Cefazolin (1 gram every 8 hours for 9 doses for a total of three days)
Number of subjects: 1354
Study: 2645933

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain
Number of subjects: 0
Study: 31317534

Group type: EXPERIMENTAL
Intervention: Standardized antibiotic stewardship quality improvement program
Number of subjects: 27
Study: 31378975

Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy (SPT) consisting of oral prophylaxis with oral hygiene instructions
Number of subjects: 62

Group type: COMPARATOR
Intervention: Supportive periodontal therapy (SPT) combined with subgingival instrumentation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy (SPT)
Number of subjects: 62
Study: 27862178

Group type: EXPERIMENTAL
Intervention: rHSA/IFNα2a 600 μg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rHSA/IFNα2a 750 μg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rHSA/IFNα2a 900 μg
Number of subjects: 32

Group type: COMPARATOR
Intervention: PEG-IFNα2a 180 μg
Number of subjects: 32
Study: 25249142

Group type: EXPERIMENTAL
Intervention: Warm-up (10 min practice session in simulation lab)
Number of subjects: 40
Study: 22914267

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 21564315

Group type: EXPERIMENTAL
Intervention: Contingent electrical stimulation (CES)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No CES (Control)
Number of subjects: 14
Study: 19451183

Group type: EXPERIMENTAL
Intervention: Wearing well-fitting masks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard hospital hygiene procedures (control)
Number of subjects: 80
Study: 16701184

Group type: EXPERIMENTAL
Intervention: mepivacaine 2%
Number of subjects: 47

Group type: COMPARATOR
Intervention: lidocaine 2%
Number of subjects: 47
Study: 12619262

Group type: EXPERIMENTAL
Intervention: Benzocaine patch (12 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 60
Study: 11218544

Group type: EXPERIMENTAL
Intervention: male and female condom plus N-9 products (vaginal suppositories, film, gel)
Number of subjects: 41

Group type: COMPARATOR
Intervention: male and female condom
Number of subjects: 41
Study: 8808885

Group type: EXPERIMENTAL
Intervention: 2.5 Hz stimulation at pulses 1 msec
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 20 Hz stimulation at pulses 1 msec
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 95 Hz stimulation at pulses 0.5 msec
Number of subjects: 33
Study: 1430286

Group type: EXPERIMENTAL
Intervention: Gingivectomy (GV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Modified Widman flap (MWF)
Number of subjects: 14
Study: 3917631

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH) using a simplified dry gas mixture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard exercise protocol ventilating ad libitum from dry air at room temperature
Number of subjects: 10
Study: 3561604

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum (DDP) 100 mg/m2 infused for 4 h on 5 consecutive days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum (DDP) 20 mg/m2 infused for 1 h on 5 consecutive days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Both administration schedules of DDP
Number of subjects: 105
Study: 29271855

Group type: EXPERIMENTAL
Intervention: Lidocaine Spray (LS) - 40 mg of 10% lidocaine spray applied thoroughly to the cervix
Number of subjects: 132

Group type: COMPARATOR
Intervention: Paracervical Block (PB) - 10 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lidocaine Spray (LS)
Number of subjects: 132
Study: 28025154

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with 4 passes
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with 6 passes
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with 4 passes in masses >2 cm
Number of subjects: 239

Group type: COMPARATOR
Intervention: EUS‐FNA with more than 4 passes
Number of subjects: 239
Study: 25794213

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) for each nerve root, 2 cycles
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham PRF (control group)
Number of subjects: 21
Study: 23758955

Group type: EXPERIMENTAL
Intervention: In-plane multiangle needle guide
Number of subjects: 16

Group type: COMPARATOR
Intervention: No needle guide (Control)
Number of subjects: 16
Study: 20354444

Group type: EXPERIMENTAL
Intervention: Community popular opinion leader intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: AIDS education comparison
Number of subjects: 0
Study: 18494842

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 165
Study: 16796897

Group type: EXPERIMENTAL
Intervention: T1G3 group
Number of subjects: 72
Study: 14604707

Group type: EXPERIMENTAL
Intervention: Bitoric ablation (Group 1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Monotoric ablation (Group 2)
Number of subjects: 15
Study: 11036470

Group type: EXPERIMENTAL
Intervention: Dose-intense M-VAC with G-CSF support
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional-dose M-VAC
Number of subjects: 162
Study: 8977854

Group type: EXPERIMENTAL
Intervention: Antral washouts followed by antibiotics and topical nasal steroids
Number of subjects: 114

Group type: COMPARATOR
Intervention: Antibiotics and topical nasal steroids alone
Number of subjects: 114
Study: 1296491

Group type: EXPERIMENTAL
Intervention: Ioversol 300
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamidol 300
Number of subjects: 0
Study: 6242801

Group type: EXPERIMENTAL
Intervention: Human insulin zinc suspension crystalline (recombinant DNA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Highly purified porcine insulin zinc suspension (mixed)
Number of subjects: 10
Study: 30797836

Group type: EXPERIMENTAL
Intervention: Healthy breakfast composition
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Higher education level, being a woman, reporting to be fit
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Preferences for low-fat, familiar or convenient foods
Number of subjects: 460
Study: 29990948

Group type: EXPERIMENTAL
Intervention: Outdoor traffic noise (modelled using the Nordic prediction model)
Number of subjects: 7321

Group type: EXPERIMENTAL
Intervention: Modelled noise levels higher than 60 dB
Number of subjects: 7321

Group type: EXPERIMENTAL
Intervention: Modelled noise for respondents whose bedroom windows faced the street
Number of subjects: 7321

Group type: EXPERIMENTAL
Intervention: Noise sensitivity
Number of subjects: 7321
Study: 27618593

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 1075
Study: 24444257

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 51
Study: 22310411

Group type: EXPERIMENTAL
Intervention: Plate fixation for open-door laminoplasty
Number of subjects: 49

Group type: COMPARATOR
Intervention: Suture group (control) for open-door laminoplasty
Number of subjects: 49
Study: 20210615

Group type: COMPARATOR
Intervention: Control clothing (CON)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Partial uniform (PART)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Full uniform (FULL)
Number of subjects: 10
Study: 18329126

Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily plus placebo (monotherapy)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg plus adefovir dipoxil 10 mg daily (combination therapy)
Number of subjects: 115
Study: 15949731

Group type: EXPERIMENTAL
Intervention: T-cell-adapted ATG induction therapy (Sangstat) 1.5 mg/kg for 3.9 ± 1.6 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group with full-dose ATG regimen (Merieux) for 8 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 12500934

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (TG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 65
Study: 9660555

Group type: COMPARATOR
Intervention: NAA/Cr ratio in right medial temporal lobe
Number of subjects: 21

Group type: COMPARATOR
Intervention: Choline/Cr ratio in left medial temporal lobe
Number of subjects: 21
Study: 7807104

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Noncemented total hip arthroplasty
Number of subjects: 60
Study: 2668140

Group type: EXPERIMENTAL
Intervention: Ruscus extract
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hesperidine methyl chalcone (HMC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of Ruscus extract and HMC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 865369

Group type: EXPERIMENTAL
Intervention: Ferro-Grad Folic
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ferro-Gradumet
Number of subjects: 103

Group type: COMPARATOR
Intervention: FGF
Number of subjects: 103

Group type: COMPARATOR
Intervention: Slow-Fe
Number of subjects: 103

Group type: COMPARATOR
Intervention: Lower dose iron group
Number of subjects: 103
Study: 31104040

Group type: EXPERIMENTAL
Intervention: 12-month multicomponent health promotion intervention including a smoking cessation and counseling program.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (CG) with no specific intervention mentioned.
Number of subjects: 222
Study: 29677565

Group type: EXPERIMENTAL
Intervention: Arm ergometer aerobic training combined with resistance training
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Treadmill aerobic training combined with resistance training
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cycle ergometer aerobic training combined with resistance training
Number of subjects: 78
Study: 27012435

Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (2, 8 & 16 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine/naloxone (2/0.5, 8/2 & 16/4 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24551053

Group type: EXPERIMENTAL
Intervention: Receiving help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observing help
Number of subjects: 0
Study: 22815837

Group type: EXPERIMENTAL
Intervention: 40 g type 2 resistant starch
Number of subjects: 12

Group type: COMPARATOR
Intervention: Energy and carbohydrate-matched placebo
Number of subjects: 12
Study: 19158197

Group type: EXPERIMENTAL
Intervention: GH treatment (1.0 mg/m².d for infants and prepubertal children; 1.0 or 1.5 mg/m².d for pubertal children)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 91
Study: 17484756

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 15098800

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 5 mg every 12 hrs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 10 mg every 12 hrs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 20 mg every 12 hrs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 40 mg every 12 hrs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metabolites (6-hydroxyoxymorphone and oxymorphone-3-glucuronide)
Number of subjects: 24
Study: 11823730

Group type: EXPERIMENTAL
Intervention: Self-monitoring of glucose levels
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring
Number of subjects: 278

Group type: COMPARATOR
Intervention: Urine glucose monitoring
Number of subjects: 278
Study: 9395005

Group type: EXPERIMENTAL
Intervention: six month preseasonal SLIT with Lolium perenne extract (n = 35)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: nine-month pre-coseasonal SLIT (n = 30 from treated group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: forty-two treated patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 54
Study: 8179173

Group type: EXPERIMENTAL
Intervention: General anaesthesia (GA) with 0.1‐0.15 mg/kg midazolam and 10 micrograms/kg fentanyl prior to skin incision; maintenance included 65% nitric oxide in oxygen and 0.1 mg increments of fentanyl as required.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined technique of dose‐reduced general anaesthesia and supplementary continuous thoracic epidural anaesthesia (bupivacaine 0.25%, sensory blockade T4 to L1‐3).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (no ibuprofen).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg i.v.) administered 15 min before induction of anaesthesia.
Number of subjects: 40
Study: 3035164

Group type: COMPARATOR
Intervention: Conventional oral hygiene procedures
Number of subjects: 347

Group type: COMPARATOR
Intervention: Sodium bicarbonate, hydrogen peroxide, and sodium chloride (S/P) oral hygiene
Number of subjects: 347

Group type: COMPARATOR
Intervention: Conventional oral hygiene procedures plus phase‐contrast demonstration
Number of subjects: 347

Group type: COMPARATOR
Intervention: S/P oral hygiene plus phase‐contrast demonstration
Number of subjects: 347
Study: 28959911

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 21

Group type: COMPARATOR
Intervention: MICT (moderate intensity continuous training)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both MICT and SIT
Number of subjects: 21
Study: 28664579

Group type: COMPARATOR
Intervention: Heparin bridging
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Uninterrupted warfarin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 25661668

Group type: EXPERIMENTAL
Intervention: Air Temperature Control (ATC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Skin Servocontrol (SSC)
Number of subjects: 38
Study: 23957018

Group type: EXPERIMENTAL
Intervention: Surgical removal of third molars
Number of subjects: 3
Study: 20861643

Group type: EXPERIMENTAL
Intervention: Specific IgE to peanut extract and recombinant Ara h 2 and Ara h 6
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Recombinant Ara h 2
Number of subjects: 237